UPDATE: Credit Suisse Downgrades Esperion Therapeutics (ESPR) to Underperform
Tweet Send to a Friend
(Updated - August 3, 2022 4:29 AM EDT)
Credit Suisse analyst Judah Frommer downgraded Esperion Therapeutics (NASDAQ: ESPR) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Credit Suisse analyst Judah Frommer downgraded Esperion Therapeutics (NASDAQ: ESPR) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
